Post on 22-Oct-2018
Commentpublierenpsycho-oncologie?
AnneBrédartPsychologue,PhD,HDR
UnitédePsycho-Oncologie
CongrèsSFPO22novembre2017
14h-18h
Pourquoiécrire?• Bâtirplusdeconnaissance• Partagerdelaconnaissance• Dénoncerdeserreurs• Montrerdelacrédibilité• Soutenirunerecherchedefinancement• Obtenirunposte• Apprendre• Etablirdesrelationsintéressantes• ….
Freinsàl’écriture
• Manqued’expérience• Mauvaiseshabitudesd’écriture• Anxiété• Perfectionnisme• Manquedeconfiance• Peurdel’échec• Résistanceauxcritiques• …
Leviers• Travailleravecdescollègues• Assureruncadrematérieladéquat• Projetréaliste,àadaptersinécessaire• Etremotivé– Objectifsprécis– Progrèsrégulier– Persévérer
Préalables• Choixd’unsujetderechercheoriginal,pertinent,utile,contemporain/avant-garde
• Elaborationd’unprotocolederechercherigoureux– Méthodologiederecherche
• Recherchedefinancement– Appelsd’offre
• Soumissionauxinstancesrèglementaires• Collecteetgestiondesdonnées• Extractiondesdonnées,nettoyage• Analyse• Tracersesdémarches– Journaldebord
Ecriture• Ecriredèsledébut– Introduction–Méthode
• Suivrelalittérature• Revoir/réécrireaufildel’analyse,del’intégrationdesdonnéesdelalittérature
• Fairerelirepremierjet
Format(1)Quelcontenude…:• Abstract?• Introduction(contexte,rationneldesquestionsposées)?
• Méthode(?• Résultats(sansjugement)?• Discussion?• Conclusion?• Implicationscliniques?
Format(2)Quelleforme…:• Titres,sous-titres• Résultats– F(1,136)=4.86,MSE =3.97,p =.029,ὴ2=.03–
• Références– StyleAPA,Harvard…
• Tableaux,figures
Style• Phrasecourte• Texteconcis• Clair• Direct• Logique• Facileàsuivre(assurersalecture)• Facileàcomprendre(pédagogique)
Pourquoiunarticleestrejeté?
• Inadaptéaujournal• Inadéquat,incomplet– Détailssurlapopulation,lesinstruments,letyped’analyse
• Manquedevaliditéinterne/externe• Surinterprétationdesrésultats• Ecritureconfuse,difficileàsuivre
Règlesdepublication
• Rôledesco-auteurs• Ordredesnoms• Collaboration/cadeau• Auteurfantôme• Conflitsd’intérêt• Fraude/plagiat
EXPÉRIENCEREJETIMMÉDIAT
DearDr. Brédart:
ThankyouforyoursubmissiontoJournalofClinicalOncology.Ihavereadyourmanuscriptinfulldetail.
Iamsorrytoreportthatweareunabletoacceptyourmanuscriptforpublication.Manyconsiderationsfactoredintoourdecision.Amongtheseconsiderationsisconcernthattheresultsofthisqualitativestudyaretoopreliminarytoinformoncologypractice. OurfeelingisthatthismanuscriptwouldbemoreappropriateforanotherjournalthatfocusestoagreaterextentthanJCOoninitialqualitativefindingsinoncology(e.g.,SupportiveCareinCancer).JournalofClinicalOncologyreceivesanaverageof5,000submissionsperyear,ofwhichmorethan3,000areOriginalReports,andlessthan13%oftheseareultimatelyacceptedforpublication.Inviewofthemanymanuscriptsthatwereceiveforconsideration,itissometimesnecessarytomakeaneditorialdecisionastowhetherapaper'spriorityishighenoughtowarrantfullreview.Rejectionofamanuscriptbaseduponpriorityconsiderationsshouldnotbetakentoimplythatthestudylacksmerit.Rather,theexpeditedreviewprocessisultimatelydesignedtopermityoutomorerapidlyresubmitthepapertoamoreappropriatejournal.
Sincerely,
PaulJacobsen,PhDAssociateEditorJournalofClinicalOncology
EXPÉRIENCERÉVISIONMAJEURE
Reviewer(s)'CommentstoAuthor:Reviewer:1
CommentstotheAuthorThemanuscriptdescribesanimportantareaofresearchintopatients'tolerabilityofMTA-relatedside-effectsusingqualitativemethodologywhichwasclearlyoutlined. Thepaperwouldbenefitfromagreaterclarityofexpression. Forexampletheabstractcontainssentenceswhicharedifficulttofollowespeciallytheconcludingsentence. Adescriptionofeligiblepatientgroupswouldbeadvisable,forexample,theabstractcouldoutlinethatpatientswithdifferentcancersreceivingMTAswereeligibleforinclusion. AnoutlinefortherationaleforincludingpatientsonMTAseitherasmonotherapy,dualMTAorincombinationwithchemotherapywhileexcludingthosereceivingMTAswithradiotherapy couldhavebeenprovided. Sideeffectsdescribedmightbeaconsequenceofthechemotherapy.Inaddition,therationaleforincludingpatientsstillontreatmentandthoseforwhomtreatmenthasbeendiscontinuedcouldbeclearlyoutlined.Therecouldbediscussionofdifferentperceptionsofsideeffectsaccordingtotreatmentsetting(metastaticoradjuvant).Finally,amoredescriptiveandcomprehensiveoverviewofthefindingswithinthetextcouldhavebeenprovided- Table2.providesillustrativeexcerptsbutquotestosupportargumentswithinthetextcouldhavebeenprovided,forexamplewithinthediscussionofsocialrepercussionsofsideeffects.
Reviewer:2
CommentstotheAuthor
CommentstotheAuthorsVeryimportantstudy!ResultsVeryinterestingandimportantresults!However,youneedtogiveamorethoughtfulpictureofthelivedexperiencesandaddmorequotestovalidateyourresults(morethanthetable).Forexample;“…theyfeltsymptomimprovementandreductioninside-effects...”(page9),Iwouldliketoknowwhatthepatientssaid,becausewhenIreadthequotesinyourtable,Ionlyreadaboutdifficultside-effects.Theresultsectionwouldalsobenefitbyincludingsomequotesaboutthepatients’sideeffectsregardingfrequency.Atp.8:“patientsdescribedasthemostintolerable,unacceptableorunbearable…”Youneverdescribewhatisseenasunbearableside-effectsforpatients?Lateryouusewordsliketolerable,unpleasant,bothersome,etc.Isthissomethingelsethanintolerable,unacceptableorunbearable?
DiscussionIthinkyouhavetheoreticalandclinicalimplicationsthatareunderdevelopedinyourdiscussionsectionandshouldbefurtherextractedfromissuesofrelevancetoEJCCreaders.Asuggestionistostartthediscussionsectionwithyourprimaryresultsinmaximum2-3linesClinical:Arepatientswellinformed,dotheyunderstandthenatureandaimofphase1trials?Sincetheyunderestimatetheside-effectsandareafraidofbeingdroppedoutand,therefore,areholdingout,aretheyrelevanttreated?Ethical:Ifpatientswithseverecancerattheendoflifechoosetobetreatedinanaggressiveway– asalastchanceand,ifyouthenhaveinmindthattheaimofphase1trialsaretoidentifytoxicityprofile,thequestionmustbeasked– istheindividualtolerabilitydefinitionrelevant?Isitpossibletousesuchadefinitioninsuchsetting?Whatabouttherapeuticmisconceptionandthefactthatpatientspreferredphysicianstomakethedecisionfordiscontinuation.Isitaproblemthatthosewhodiscontinuedtrialparticipationmaybearesufferingfromlong-termside-effects,inadditiontoloosingtheirlasthope?Scientific:Theremightbeariskofbiasandincorrectresults(underreportedside-effects,tohighprescribeddrugs,unnecessaryadverseside-effects,whichalsoaffectphase2participants).Isthenthedefinitionofmedicaltolerabilityadequate?Isitpossibletoprovideanexcellentsafetyprofile,withalowincidenceofsideeffects?Yousaythat”patientsmostlyreportedacceptabletreatmenttolerance”(page11).Whataboutthosewhodiscontinuedthetrial?Clinicalimplicationsshouldbeadded.Whatcanwelearnfromyourresults?
Ressources• PublicationmanualoftheAPA,2010.
• Bragge,BMCMedResMeth,2011:TheGlobalEvidenceMappingInitiative:scopingresearchinbroadtopicareas.
• Baumeister,Rev Gen Psy,1997:Writing narrativereview.
• O'Brien,Acad Med,2014:Standardsforreportingqualitativeresearch:asynthesisofrecommendations.
• Liumbruno,BloodTransfus ,2013:Howtowriteascientificmanuscriptforpublication.
• Moher,BMJ,2009:Preferredreportingitemsforsystematicreviewsandmeta-analyses:thePRISMA statement.
• vonElm,AnnInterMed,2007:TheStrengtheningtheReportingofObservationalStudiesinEpidemiology(STROBE)statement:guidelinesforreportingobservationalstudies.